Harmony Biosciences Holdings (HRMY) Total Current Liabilities (2019 - 2026)

Harmony Biosciences Holdings has disclosed Total Current Liabilities across 8 years of filings, most recently posting $217.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $217.3 million, up 24.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $217.3 million (up 24.11% YoY), and the FY2025 annual result was $252.1 million, up 44.01% from the prior year.
• Total Current Liabilities came in at $217.3 million for Q1 2026 at Harmony Biosciences Holdings, down from $252.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $252.1 million in Q4 2025 to a low of $56.5 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $154.3 million (2024), against an average of $144.0 million.
• Across the five-year window, Total Current Liabilities surged 125.43% in 2022 and climbed 4.7% in 2023, its largest moves.
• Harmony Biosciences Holdings' Total Current Liabilities stood at $78.9 million in 2022, then jumped by 107.62% to $163.8 million in 2023, then advanced by 6.9% to $175.1 million in 2024, then jumped by 44.01% to $252.1 million in 2025, then retreated by 13.8% to $217.3 million in 2026.
• The last three Total Current Liabilities figures came in at $217.3 million (Q1 2026), $252.1 million (Q4 2025), and $223.4 million (Q3 2025), per Business Quant data.